{"id":2947984,"date":"2021-10-15T07:15:00","date_gmt":"2021-10-15T11:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/"},"modified":"2025-03-07T23:38:15","modified_gmt":"2025-03-08T04:38:15","slug":"merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/","title":{"rendered":"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older"},"content":{"rendered":"<div class=\"q4default\">\n<p>    KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211;<br \/>\nMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by <i>Streptococcus pneumoniae<\/i> in individuals 18 years of age and older.\n<\/p>\n<p>\nThe CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year.\n<\/p>\n<p>\nThe CHMP opinion was based on data from seven randomized, double-blind clinical studies evaluating VAXNEUVANCE in 7,438 individuals from a variety of adult populations and clinical circumstances. In July 2021, VAXNEUVANCE received approval from the U.S. Food and Drug Administration (FDA) for active immunization for the prevention of invasive disease caused by <i>Streptococcus pneumoniae<\/i> serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years and older.\n<\/p>\n<p>\n  <b>About Pneumococcal Disease<\/b>\n<\/p>\n<p>\nThe global prevalence of pneumococcal disease, an infection caused by bacteria called <i>Streptococcus pneumoniae<\/i>, is evolving. Highly aggressive strains, or serotypes, threaten to put more people at risk for invasive pneumococcal illnesses such as bacteremia (infection in the bloodstream); bacteremic pneumonia (pneumonia with bacteremia); and meningitis (infection of the coverings of the brain and spinal cord), as well as non-invasive pneumonia (when pneumococcal disease is confined to the lungs). While healthy adults can suffer from pneumococcal disease, patient populations particularly vulnerable to infection include older adults such as those 65 years of age and older, people with HIV, and those with certain chronic health conditions.\n<\/p>\n<p>\n  <b>About VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)<\/b>\n<\/p>\n<p>\nVAXNEUVANCE, Merck\u2019s 15-valent pneumococcal conjugate vaccine, consists of purified capsular polysaccharides from <i>S. pneumoniae<\/i> serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to CRM197 carrier protein.\n<\/p>\n<p>\nVAXNEUVANCE is indicated in the U.S. for active immunization of adults 18 years of age and older for the prevention of invasive disease caused by the <i>S. pneumoniae<\/i> serotypes contained in the vaccine.\n<\/p>\n<p>\n  <b>U.S. Select Safety Information for VAXNEUVANCE in Adults 18 Years of Age and Older<\/b>\n<\/p>\n<p>\nDo not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.\n<\/p>\n<p>\nSome individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.\n<\/p>\n<p>\nThe most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection site swelling (21.7%), injection site erythema (15.1%) and arthralgia (12.7%).\n<\/p>\n<p>\nThe most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection site swelling (15.4%), injection site erythema (10.9%) and arthralgia (7.7%).\n<\/p>\n<p>\nVaccination with VAXNEUVANCE may not protect all vaccine recipients.\n<\/p>\n<p>\n  <b>Merck\u2019s Commitment to Infectious Diseases<\/b>\n<\/p>\n<p>\nFor more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases. In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, Merck has multiple programs that span discovery through late-stage development. To learn more about Merck\u2019s infectious diseases pipeline, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=52509628&amp;newsitemid=20211015005281&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=b3a8daf215824e2f6beb3500a1b2129c\">vip2-msd.com\/merckcom-migrated<\/a>.\n<\/p>\n<p>\n  <b>About Merck<\/b>\n<\/p>\n<p>\nFor over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=52509628&amp;newsitemid=20211015005281&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=1a477fe772afd8cd8adb1474b465a0bb\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.\n<\/p>\n<p>\n  <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n<\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2020 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52509628&amp;newsitemid=20211015005281&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=09f6b48a9b2cae1f60284321afb93670\">www.sec.gov<\/a>).\n<\/p>\n<p>\n  <b>Please see U.S. Prescribing Information for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_pi.pdf&amp;esheet=52509628&amp;newsitemid=20211015005281&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_pi.pdf&amp;index=4&amp;md5=be878abb44001191c78e483c2727a60c\">https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_pi.pdf<\/a> and U.S. Patient Information at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_ppi.pdf&amp;esheet=52509628&amp;newsitemid=20211015005281&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_ppi.pdf&amp;index=5&amp;md5=44a6fdaf0b97c5bc37c30911f0404b63\">https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_ppi.pdf<\/a>.<\/b>\n<\/p>\n<p>\n  <img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n  <span class=\"bwct31415\"><\/span>\n<\/p>\n<p id=\"mmgallerylink\">\n  <span id=\"mmgallerylink-phrase\">View source version on <a href=\"http:\/\/businesswire.com\">businesswire.com<\/a>: <\/span><br \/>\n  <span id=\"mmgallerylink-link\"><br \/>\n    <a href=\"https:\/\/www.businesswire.com\/news\/home\/20211015005281\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20211015005281\/en\/<\/a><br \/>\n  <\/span>\n<\/p>\n<p>\nMedia Contacts:<\/p>\n<p>Melissa Moody<br \/>\n<br \/>(215) 407-3536<\/p>\n<p>Steve Wanczyk<br \/>\n<br \/>(267) 305-5563<\/p>\n<p>Investor Contacts:<\/p>\n<p>Peter Dannenbaum<br \/>\n<br \/>(908) 740-1037<\/p>\n<p>Raychel Kruper<br \/>\n<br \/>(908) 740-2107\n<\/p>\n<p>Source: Merck &amp; Co., Inc.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year. The CHMP opinion was based on data from seven randomized, double-blind clinical studies evaluating VAXNEUVANCE in 7,438 individuals from a variety of adult populations and clinical circumstances. In July 2021, VAXNEUVANCE received approval from the U.S. Food and Drug Administration (FDA) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,56],"class_list":["post-2947984","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year. The CHMP opinion was based on data from seven randomized, double-blind clinical studies evaluating VAXNEUVANCE in 7,438 individuals from a variety of adult populations and clinical circumstances. In July 2021, VAXNEUVANCE received approval from the U.S. Food and Drug Administration (FDA) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:38:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/\",\"name\":\"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-10-15T11:15:00+00:00\",\"dateModified\":\"2025-03-08T04:38:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/","og_locale":"en_US","og_type":"article","og_title":"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year. The CHMP opinion was based on data from seven randomized, double-blind clinical studies evaluating VAXNEUVANCE in 7,438 individuals from a variety of adult populations and clinical circumstances. In July 2021, VAXNEUVANCE received approval from the U.S. Food and Drug Administration (FDA) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:38:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/","name":"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","datePublished":"2021-10-15T11:15:00+00:00","dateModified":"2025-03-08T04:38:15+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20211015005281r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c470ab72-8b13-4ccb-953d-341ad15170d4","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_multimedia\/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg","size":"211320","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Receives-Positive-CHMP-Opinion-for-VAXNEUVANCE-Pneumococcal-15-valent-Conjugate-Vaccine-in-Individuals-18-Years-of-Age-and-Older-2021.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/2947984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/2947984\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=2947984"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=2947984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}